Loxo Oncology: New Loxo@Lilly facility brings oncology R&D to Louisville
LOUISVILLE - About three years after pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) acquired Loxo Oncology Inc. in a deal worth about $8 billion, the merged companies stepped into ... Continued
Read full article »
CEO
Jacob S. Van Naarden
Loxo Oncology develops and markets genomic medicines for the treatment of cancer.
Read more